Course Opens
12/10/2025
Credits
1
Credit Expires
12/19/2026
Neuroendocrine prostate cancer (NEPC) and other aggressive histologic variants of prostate cancer (PC) represent rare but clinically devastating disease phenotypes. These tumors progress rapidly and often evade detection through conventional measures such as PSA monitoring and standard biopsies creating challenges for timely recognition and optimal treatment selection. As a result, patients may miss opportunities for early therapeutic intervention and access to novel therapies.
In this CE Concepts infographic, the multidisciplinary care team will be equipped with practical strategies to improve recognition, diagnostic accuracy, and coordinated care for NEPC and other high-risk prostate cancer phenotypes. Faculty experts will showcase how a collaborative approach that integrates advanced imaging, histopathology, and molecular profiling together with the latest advances in biomarkers, therapies, and clinical trial opportunities translates cutting-edge science into actionable clinical pearls. By leveraging innovative, interactive education, this program will empower oncologists, urologists, radiologists, pathologists, advanced practitioners, and the broader multidisciplinary team with strategies that can be applied immediately to ensure timely evidence-based decisions and improve patient outcomes.
At the conclusion of this activity, learners will be able to better:
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Academic pathologists, radiologists, surgical oncologists, medical oncologists, genitourinary (GU) oncologists, neuroendocrine oncologists, oncology specialized nurse practitioners (NPs), physician associates (PAs), pharmacists and nurses
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-25-011-H01-P).
This activity is designated for 1.00 contact hours.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 12/19/2026. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Aggarwal reports the following financial relationships:
Advisory Board: Alessa Therapeutics; AstraZeneca; Auron Therapeutics; Bayer; Daiichi Sankyo, Inc.; FibroGen, Inc.; Flare Therapeutics Inc.; Harpoon Therapeutics, Inc.; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; ORIC Pharmaceuticals, Inc.; Peptone; and Vir Biotechnology, Inc.
Consultant: Aquilo Capital; Boxer Capital Management; Curio Science; DAVA Oncology; EcoR1 Capital; MJH Life Sciences; Pfizer Inc.; and Slingshot Capital Inc.
Research Support: Amgen Inc.; AstraZeneca; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Zenith Epigenetics
The following individuals have no financial relationships to disclose:
Jeffrey Helfand, DO (Peer Reviewer)
Thomas Mitchell, MSW, LSW (Planning Committee)
Kashemi D. Rorie, PhD (Planning Committee)
Taylor Wallace, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
IN-014-121925-44
Call us at 859-260-1717 • info@ceconcepts.com
